These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 26154072)

  • 21. Management of hypertrophic cardiomyopathy.
    Enriquez AD; Goldman ME
    Ann Glob Health; 2014; 80(1):35-45. PubMed ID: 24751563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inverted U-Shaped Relation Between the Risk of Sudden Cardiac Death and Maximal Left Ventricular Wall Thickness in Hypertrophic Cardiomyopathy.
    O'Mahony C; Jichi F; Monserrat L; Ortiz-Genga M; Anastasakis A; Rapezzi C; Biagini E; Gimeno JR; Limongelli G; McKenna WJ; Omar RZ; Elliott PM;
    Circ Arrhythm Electrophysiol; 2016 Jun; 9(6):. PubMed ID: 27217341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiac magnetic resonance imaging findings predict major adverse events in apical hypertrophic cardiomyopathy.
    Hanneman K; Crean AM; Williams L; Moshonov H; James S; Jiménez-Juan L; Gruner C; Sparrow P; Rakowski H; Nguyen ET
    J Thorac Imaging; 2014 Nov; 29(6):331-9. PubMed ID: 25314027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk stratification in hypertrophic cardiomyopathy.
    Marrakchi S; Kammoun I; Bennour E; Laroussi L; Kachboura S
    Herz; 2020 Feb; 45(1):50-64. PubMed ID: 29696341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sudden Cardiac Death Risk Stratification and the Role of the Implantable Cardiac Defibrillator.
    Iwai S
    Cardiol Clin; 2019 Feb; 37(1):63-72. PubMed ID: 30447717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM).
    O'Mahony C; Jichi F; Ommen SR; Christiaans I; Arbustini E; Garcia-Pavia P; Cecchi F; Olivotto I; Kitaoka H; Gotsman I; Carr-White G; Mogensen J; Antoniades L; Mohiddin SA; Maurer MS; Tang HC; Geske JB; Siontis KC; Mahmoud KD; Vermeer A; Wilde A; Favalli V; Guttmann OP; Gallego-Delgado M; Dominguez F; Tanini I; Kubo T; Keren A; Bueser T; Waters S; Issa IF; Malcolmson J; Burns T; Sekhri N; Hoeger CW; Omar RZ; Elliott PM
    Circulation; 2018 Mar; 137(10):1015-1023. PubMed ID: 29191938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Hypertrophic cardiomyopathy and sudden cardiac death--ICD indications in the margin of uncertainty].
    Fauchère I; Duru F
    Praxis (Bern 1994); 2009 Aug; 98(17):941-52. PubMed ID: 19711287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: a meta-analysis.
    Briasoulis A; Mallikethi-Reddy S; Palla M; Alesh I; Afonso L
    Heart; 2015 Sep; 101(17):1406-11. PubMed ID: 26060120
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sports and Exercise in Athletes with Hypertrophic Cardiomyopathy.
    Alpert C; Day SM; Saberi S
    Clin Sports Med; 2015 Jul; 34(3):489-505. PubMed ID: 26100424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Usefulness of cardiac magnetic resonance in assessing the risk of ventricular arrhythmias and sudden death in patients with hypertrophic cardiomyopathy.
    Leonardi S; Raineri C; De Ferrari GM; Ghio S; Scelsi L; Pasotti M; Tagliani M; Valentini A; Dore R; Raisaro A; Arbustini E
    Eur Heart J; 2009 Aug; 30(16):2003-10. PubMed ID: 19474054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and prognostic impact of chronotropic incompetence in patients with hypertrophic cardiomyopathy.
    Magri D; Agostoni P; Sinagra G; Re F; Correale M; Limongelli G; Zachara E; Mastromarino V; Santolamazza C; Casenghi M; Pacileo G; Valente F; Morosin M; Musumeci B; Pagannone E; Maruotti A; Uguccioni M; Volpe M; Autore C
    Int J Cardiol; 2018 Nov; 271():125-131. PubMed ID: 30087038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sudden death and hypertrophic cardiomyopathy: a review.
    Ly HQ; Greiss I; Talakic M; Guerra PG; Macle L; Thibault B; Dubuc M; Roy D
    Can J Cardiol; 2005 Apr; 21(5):441-8. PubMed ID: 15861263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk factors and mode of death in isolated hypertrophic cardiomyopathy in children.
    Decker JA; Rossano JW; Smith EO; Cannon B; Clunie SK; Gates C; Jefferies JL; Kim JJ; Price JF; Dreyer WJ; Towbin JA; Denfield SW
    J Am Coll Cardiol; 2009 Jul; 54(3):250-4. PubMed ID: 19589438
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Ackerman MJ; Casey SA; Semsarian C; Estes NA; Shannon KM; Ashley EA; Day SM; Pacileo G; Formisano F; Devoto E; Anastasakis A; Bos JM; Woo A; Autore C; Pass RH; Boriani G; Garberich RF; Almquist AK; Russell MW; Boni L; Berger S; Maron MS; Link MS
    J Am Coll Cardiol; 2013 Apr; 61(14):1527-35. PubMed ID: 23500286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk stratification in pediatric hypertrophic cardiomyopathy: Insights for bridging the evidence gap?
    Nakano SJ; Menon SC
    Prog Pediatr Cardiol; 2018 Jun; 49():31-37. PubMed ID: 31097901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Syncope, other risk factors, and the implantable defibrillator for sudden death prevention in hypertrophic cardiomyopathy.
    Cotiga D; Ehlert F; Sherrid M
    Anadolu Kardiyol Derg; 2006 Dec; 6 Suppl 2():55-60. PubMed ID: 17162272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variables associated with contrast-enhanced cardiovascular magnetic resonance in hypertrophic cardiomyopathy: clinical implications.
    Payá E; Marín F; González J; Gimeno JR; Feliu E; Romero A; Ruiz-Espejo F; Roldán V; Climent V; de la Morena G; Valdés M
    J Card Fail; 2008 Jun; 14(5):414-9. PubMed ID: 18514934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [New strategies for assessing the risk of sudden cardiac death in hypertrophic cardiomyopathy].
    Jaworski K; Możeńska O; Kosior DA
    Pol Merkur Lekarski; 2016 Aug; 41(242):65-9. PubMed ID: 27591441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Assessment of risk of sudden cardiac death in patients with hypertrophic cardiomyopathy].
    Attanasio P; Blaschke F; Pieske B; Tschöpe C; Haverkamp W
    Dtsch Med Wochenschr; 2016 Jul; 141(14):1035-9. PubMed ID: 27404936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Family History of Sudden Death Should Not Be a Primary Indication for an Implantable Cardioverter Defibrillator in Hypertrophic Cardiomyopathy.
    Watkinson OT; Elliott PM
    Can J Cardiol; 2015 Nov; 31(11):1407-9. PubMed ID: 26518447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.